NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis $1.60 +0.04 (+2.24%) Closing price 04:00 PM EasternExtended Trading$1.60 0.00 (0.00%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sunshine Biopharma Stock (NASDAQ:SBFM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sunshine Biopharma alerts:Sign Up Key Stats Today's Range$1.56▼$1.6150-Day Range$1.23▼$1.7052-Week Range$1.17▼$7.18Volume74,803 shsAverage Volume599,689 shsMarket Capitalization$7.27 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. Read More Sunshine Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreSBFM MarketRank™: Sunshine Biopharma scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSunshine Biopharma has received no research coverage in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sunshine Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.09% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 38.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.09% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 38.34%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.33 News SentimentSunshine Biopharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sunshine Biopharma this week, compared to 0 articles on an average week.Search Interest2 people have searched for SBFM on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Sunshine Biopharma is held by insiders.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBFM Stock News HeadlinesSunshine Biopharma (NASDAQ:SBFM) Upgraded by Wall Street Zen to "Hold" RatingJuly 6, 2025 | americanbankingnews.comSunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - MorningstarJuly 3, 2025 | morningstar.comM$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 10 at 2:00 AM | Brownstone Research (Ad)SBFM - Sunshine Biopharma Inc News - MorningstarJuly 3, 2025 | morningstar.comMSunshine Biopharma, Inc. (SBFM) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comSunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’June 11, 2025 | msn.comSunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSee More Headlines SBFM Stock Analysis - Frequently Asked Questions How have SBFM shares performed this year? Sunshine Biopharma's stock was trading at $3.00 on January 1st, 2025. Since then, SBFM stock has decreased by 46.8% and is now trading at $1.5950. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The business had revenue of $8.90 million for the quarter. Sunshine Biopharma had a negative net margin of 13.88% and a negative trailing twelve-month return on equity of 21.25%. When did Sunshine Biopharma's stock split? Shares of Sunshine Biopharma reverse split before market open on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sunshine Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/15/2025Today7/10/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SBFM CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Sunshine Biopharma$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+840.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($150.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.13 million Net Margins-13.88% Pretax Margin-14.70% Return on Equity-21.25% Return on Assets-16.89% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio2.19 Sales & Book Value Annual Sales$34.87 million Price / Sales0.21 Cash FlowN/A Price / Cash FlowN/A Book Value$9.10 per share Price / Book0.18Miscellaneous Outstanding Shares4,560,000Free Float4,551,000Market Cap$7.27 million OptionableNot Optionable Beta1.44 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:SBFM) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.